Evidence map›Paper›PMID 29928160›Full record

ArticleGastroenterology & hepatology2018

Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis.

Runalia Bahar, Kimberly A Wong, Chung H Liu, Christopher L Bowlus

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Gastroenterology & hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Runalia BaharDr Bahar is a hospitalist at the University of California Davis Medical Center in Sacramento, California. Dr Wong is a chief resident in the Department of Internal Medicine at the University of California Davis School of Medicine in Sacramento, California. Mr Liu is a staff member and Dr Bowlus is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine.
Kimberly A WongDr Bahar is a hospitalist at the University of California Davis Medical Center in Sacramento, California. Dr Wong is a chief resident in the Department of Internal Medicine at the University of California Davis School of Medicine in Sacramento, California. Mr Liu is a staff member and Dr Bowlus is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine.
Chung H LiuDr Bahar is a hospitalist at the University of California Davis Medical Center in Sacramento, California. Dr Wong is a chief resident in the Department of Internal Medicine at the University of California Davis School of Medicine in Sacramento, California. Mr Liu is a staff member and Dr Bowlus is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine.
Christopher L BowlusDr Bahar is a hospitalist at the University of California Davis Medical Center in Sacramento, California. Dr Wong is a chief resident in the Department of Internal Medicine at the University of California Davis School of Medicine in Sacramento, California. Mr Liu is a staff member and Dr Bowlus is the Lena Valente Professor and Chief of the Division of Gastroenterology and Hepatology at the University of California Davis School of Medicine.
University of California Davis Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary biliary cholangitis (PBC) is an autoimmune inflammatory liver disease of the interlobular bile ducts that can lead to cirrhosis and liver failure. Until recently, the only effective treatment was ursodeoxycholic acid (UDCA). However, up to 40% of PBC patients have an inadequate response to UDCA and may continue to have disease progression. Several models have been developed, including the UK-PBC and GLOBE scores, to assist in identifying patients who may benefit from second-line therapies, such as the farnesoid X receptor (FXR) agonist obeticholic acid (OCA). The addition of OCA can significantly improve serum alkaline phosphatase and total bilirubin, which are strong surrogate markers of clinical outcomes in PBC. Other alternatives, including the peroxisome proliferator-activated receptor (PPAR)-α agonists fenofibrate and bezafibrate, may also improve liver biochemistries in PBC patients with an inadequate response to UDCA, but further study is needed to demonstrate their safety and long-term efficacy. Other novel agents, including those targeting the FXR pathway and PPAR-δ agonists, have shown promising results and may alter the therapeutic landscape of PBC in the near future. For now, OCA remains the only approved second-line agent for PBC patients with an inadequate response to UDCA while results of long-term studies of its safety and clinical benefit are awaited.

Indexed as

farnesoid X receptorFGF19 analogfibrateperoxisome proliferator-activated receptor agonistPrimary biliary cholangitistherapy

Identifiers

PMID29928160
PMCPMC6004046
OpenAlexW2810924171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.